Technique can be used to better categorize patients with neurological disease, according to their therapeutic needs
Personalized medicine – delivering therapies specially tailored to a patient’s unique physiology – has been a goal of researchers and doctors for a long time. New research provides a way of delivering personalized treatments to patients with neurological disease.
On April 20, 2018, Canadian, Chinese and Cuban neuroscience institutes strengthened an existing partnership with the signing of a memorandum of understanding in Chengdu, China.
Partners in the agreement include The Montreal Neurological Institute and Hospital (The Neuro) of McGill University, The Cuban Neuroscience Center, The University of Electronic Sciences and Technology of China, The West China Hospital, and The Tianfu New Area of Chengdu (TFNA).
The Neuro is recognized worldwide as a leader in epilepsy research and treatment. From the beginning, Neuro founder, Dr. Wilder Penfield, made epilepsy a central focus. He and his colleagues developed a surgical treatment for epilepsy patients known as the “Montreal Procedure,” which today is in use throughout the world. The Neuro became a pioneer in studying epilepsy through the use of electroencephalography (EEG) and magnetic resonance imaging (MRI).
Québec Science magazine’s 25-year tradition continues: every fall, a jury comprised of researchers and journalists selects the top 10 most impressive discoveries in Quebec in the past year and the public is asked to vote to select the winner. This year, a cancer-detection probe was chosen by nearly a third of approximately 4,400 votes cast in the 2017 Discovery of the Year contest.
Congratulations to Assistant Professor Dr. Huy Bui, who has been named a 2017 CIFAR Azrieli Global Scholar!
Collaboration between departmental members Drs. D. Reinhardt and P. Campeau has received new 5-year funding from the Canadian Institutes of Health Research for the grant entitled “Role of fibronectin mutations in spondylometaphyseal dysplasia and idiopathic scoliosis” in the amount of $680,850. Congratulations!
Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
Canadian Open Neuroscience Platform will make disseminating and publishing data easier
Modern neuroscience research can produce massive amounts of data, which researchers can use to find patterns revealing anything from the first physiological signs of Alzheimer’s disease to a new drug target that could stop neurodegeneration. However, this data must be stored, processed, and distributed effectively.
New research has drawn a link between changes in the brain’s anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer’s disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Three MNI researchers have received grants from the ALS Society of Canada worth a total of more than $2 million.
Enjoyment of music is considered a subjective experience; what one person finds gratifying, another may find irritating. Music theorists have long emphasized that although musical taste is relative, our enjoyment of music, be it classical or heavy metal, arises, among other aspects, from structural features of music, such as chord or rhythm patterns that generate anticipation and expectancy.
Lawyers representing both sides in concussion lawsuits against sports leagues may eventually have a new tool at their disposal: a diagnostic signature that uses artificial intelligence to detect brain trauma years after it has occurred.
In an article published in Nature on Feb. 15, 2017, researchers, including principal investigators from the Montreal Neurological Institute’s McConnell Brain Imaging Centre (BIC), used magnetic resonance imaging (MRI) to predict the development of autism in babies.
Once again the Cystic Fibrosis Translational Research Centre (CFTRc) team from McGill University participated in the annual Walk to Make Cystic Fibrosis History. As a nation, Canada raised $3 million dollars and counting for Cystic Fibrosis research and care.
